A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day.
A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day.
复制标题
单一的矢量热脉动处理用于Meibomian腺功能障碍会增加舒适的隐形眼镜每天大约4个小时。
DOI：
10.2147/opth.s153297
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Srinivasan S
中科院分区：
文献类型：
--
作者：
Blackie CA;Coleman CA;Nichols KK;Jones L;Chen PQ;Melton R;Kading DL;O'Dell LE;Srinivasan S
目的：评价单次矢量热脉动(VTP)治疗伴有汗腺功能障碍(MGD)和干眼症状的隐形眼镜佩戴者的疗效。这项前瞻性、无显著风险、开放标签、随机、多中心的临床试验包括55名患有MGD和蒸发性干眼的软性隐形眼镜(SCL)佩戴者。受试者被随机分成单独的VTP治疗组或未治疗的对照组。对照组在3个月时接受交叉VTP治疗(交叉治疗组)。主要疗效指标为交叉治疗组在基线、VTP治疗后1个月和3个月以及VTP治疗后1个月进行的眉板腺分泌物(MGS)评分和眼干的标准患者评估(SPEED)。研究变量包括荧光素泪液破裂时间(TBUT)、眼睑雨刷上皮病(LWE)、眼睑平行结膜皱褶(LIPCOF)、眼表染色、非处方药(OTC)滴眼次数和舒适配戴隐形眼镜的时间。治疗3个月后，与对照组相比，治疗组在MGS(12.4±9.1vs1.4±6.4，p<；0.0001)、速度(−8.4±4.7vs0.7±4.4，p<；0.0001)和探索性变量(tBUT、LWE和非处方药停用频率)方面的平均变化显著高于对照组。术后1个月平均舒适隐形眼镜佩戴时间增加4.0±3.9h。持续3个月，对照组无变化。交叉治疗组在VTP术后1个月时显示与治疗组相似的结果。在患有MGD的SCL佩戴者中，与未治疗的对照组相比，单一的VTP治疗显著改善了平均眉板腺功能，并显著减少了干眼症状和体征。治疗使平均佩戴舒适镜片的时间增加了4小时(大约是治疗前的两倍)。这种情况在治疗后平均持续长达3个月。
To evaluate the effect of a single vectored thermal pulsation (VTP) treatment in contact lens wearers with meibomian gland dysfunction (MGD) and dry eye symptoms. The prospective, nonsignificant risk, open-label, randomized, multi-center clinical trial included 55 soft contact lens (SCL) wearers with MGD and evaporative dry eye. Subjects were randomized to the single VTP treatment group or an untreated control. The controls received a crossover VTP treatment at 3 months (crossover treatment group). Primary effectiveness measures were meibomian gland secretion (MGS) score and Standard Patient Evaluation of Eye Dryness (SPEED) that were evaluated at baseline, at 1 and 3 months post-VTP treatment, and at 1 month post-VTP treatment in the crossover treatment group. Exploratory variables included fluorescein tear break-up time (TBUT), lid wiper epitheliopathy (LWE), lid parallel conjunctival folds (LIPCOF), ocular surface staining, frequency of over-the-counter (OTC) drop use, and hours of comfortable contact lens wear. At 3 months, the treatment group showed significantly greater mean change from baseline in MGS (12.4±9.1 vs 1.4±6.4, p<0.0001), SPEED (−8.4±4.7 vs −0.7±4.4, p<0.0001) and significantly greater improvement in exploratory variables (TBUT, LWE, and frequency of OTC drop use) relative to the controls. Mean comfortable contact lens wearing time increased by 4.0±3.9 hours at 1 month. This was sustained for 3 months with no change in the control group. The crossover treatment group demonstrated similar results to the treatment group at 1 month post-VTP. In SCL wearers with MGD, a single VTP treatment significantly improved mean meibomian gland function and significantly reduced dry eye signs and symptoms compared to an untreated control. The treatment increased mean comfortable lens wearing time by 4 hours (approximately doubling the pretreatment findings). This was sustained for up to 3 months post-treatment on average.